Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.3152W HIGH $15.10
Volume
1.11 M
Value Traded
16.02 M
Short % Float
14.1%
-6.61%Week
-25.51%1 Month
-10.08%3 Month
-2.37%6 Month
+75.6%5 Year
+75.6%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
676.76 M
EPS (TTM)
-0.56
P/E Ratio
-
Ent. Value
444.65 M
Total Shares
71.54 M
Float Shares
68.22 M
Insiders
17.71%
Institutions
67.62%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
IMMX Catalyst Timeline
Dated clinical, regulatory and corporate events for Immix Biopharma, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Immix Biopharma, Inc.
184Total events
8Upcoming
34Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Interim Efficacy DataNXC-201Clinical Data
Interim update: 89% (40/45) complete response rate across all NEXICART-2 patients by independent review committee
relapsed/refractory AL Amyloidosissource ↗
◆Topline ReadoutNXC-201Clinical Data
Topline NEXICART-2 results expected
relapsed/refractory AL Amyloidosissource ↗
●Timing GuidanceNXC-201Presentation
BLA submission planned after topline results
relapsed/refractory AL Amyloidosissource ↗
▼Equity OfferingCorporate
Pricing of $150 million underwritten offering of common stock at $8.94 per share
▲Full ResultsNXC-201Clinical Data
Interim update: 95% CR rate, all four MRD-negative patients converted to CR
relapsed/refractory AL Amyloidosissource ↗
◆Topline ReadoutNXC-201Clinical Data
Final topline clinical data readout expected Q2/Q3 2026
relapsed/refractory AL Amyloidosissource ↗
▲Enrollment CompleteNXC-201Trial
Enrollment completion of NEXICART-2 trial
relapsed/refractory AL Amyloidosissource ↗
◆Oral PresentationPresentation
Presentation at Leerink Partners 2026 Global Healthcare Conference
▲Breakthrough Therapy DesignationNXC-201Designation
FDA granted Breakthrough Therapy Designation for NXC-201
relapsed/refractory AL Amyloidosissource ↗
▼Equity OfferingCorporate
Closing of upsized $100 million underwritten offering of common stock and pre-funded warrants
▼Equity OfferingCorporate
Pricing of upsized $100 million underwritten offering of common stock and pre-funded warrants
▲Oral PresentationNXC-201Presentation
Oral presentation of positive Phase 2 NXC-201 results at ASH 2025
relapsed/refractory AL Amyloidosissource ↗
◆Oral PresentationNXC-201Presentation
NXC-201 abstract presentation at ASH 2025 Annual Meeting
relapsed/refractory AL Amyloidosissource ↗
◆Oral PresentationPresentation
Presentation at 37th Annual Piper Sandler Healthcare Conference
◆Oral PresentationPresentation
Fireside Chat at Guggenheim 2nd Annual Healthcare Innovation Conference
◆Enrollment CompleteNXC-201Trial
Enrollment completion for NEXICART-2
relapsed/refractory AL Amyloidosissource ↗
▲Enrollment MilestoneNXC-201Trial
50% enrollment milestone surpassed in NEXICART-2
relapsed/refractory AL Amyloidosissource ↗
▲Enrollment UpdateNXC-201Trial
NEXICART-2 trial sites expanded to 18
relapsed/refractory AL Amyloidosissource ↗
▲FDA Feedback ReceivedFDA Meeting
Immix Biopharma selected to attend FDA CEO Forum led by FDA Commissioner
◆Oral PresentationNXC-201Presentation
ASCO oral presentation of updated NXC-201 results
relapsed/refractory AL Amyloidosissource ↗
▲Primary Endpoint MetNXC-201Clinical Data
NXC-201 met primary endpoint with 70% CR rate in NEXICART-2 interim results
relapsed/refractory AL Amyloidosissource ↗
▲Primary Endpoint MetNXC-201Clinical Data
Primary endpoint met at interim analysis
relapsed/refractory AL Amyloidosissource ↗
▲Oral PresentationNXC-201Presentation
Interim results presented at ASCO 2025
relapsed/refractory AL Amyloidosissource ↗
◆Oral PresentationNXC-201Presentation
Phase 1/2 interim readout selected for oral presentation at ASCO 2025
relapsed/refractory AL Amyloidosissource ↗
▲Enrollment UpdateNXC-201Trial
14 U.S. sites actively enrolling in NEXICART-2
relapsed/refractory AL Amyloidosissource ↗
▲Enrollment MilestoneNXC-201Trial
10 U.S. sites added since last update
relapsed/refractory AL Amyloidosissource ↗
◆Interim AnalysisNXC-201Trial
Interim clinical data readout expected Q2/Q3 2025
relapsed/refractory AL Amyloidosissource ↗
▲RMATNXC-201Designation
FDA RMAT designation granted for NXC-201
relapsed/refractory AL Amyloidosissource ↗
▲Enrollment UpdateNXC-201Trial
Enrollment accelerating in NEXICART-2 after safety run-in completion
relapsed/refractory AL Amyloidosissource ↗
▲Primary Endpoint MetNXC-201Clinical Data
NEXICART-2 primary endpoint met at interim results presented at ASCO 2025
relapsed/refractory AL Amyloidosissource ↗
◆Oral PresentationNXC-201Presentation
Interim results of NXC-201 presented at ASCO 2025 oral presentation
relapsed/refractory AL Amyloidosissource ↗
▲Enrollment CompleteNXC-201Trial
Safety run-in segment completed with 6 patients
relapsed/refractory AL Amyloidosissource ↗
▲Enrollment UpdateNXC-201Trial
Accelerating enrollment across U.S. sites at 450M dose
relapsed/refractory AL Amyloidosissource ↗
◆Timing GuidanceNXC-201Presentation
Next program update expected Q1 2025
relapsed/refractory AL Amyloidosissource ↗
▲Topline ReadoutNXC-201Clinical Data
Positive U.S. clinical data from first four patients in NEXICART-2 trial
relapsed/refractory AL Amyloidosissource ↗
◆Quarterly UpdateNXC-201Corporate
Conference call to provide update on positive new developments regarding CAR-T NXC-201
relapsed/refractory AL Amyloidosissource ↗
▲Oral PresentationNXC-201Presentation
NXC-201 ASH 2024 oral presentation of updated Phase 1b/2 data
relapsed/refractory AL Amyloidosissource ↗
▲Full ResultsNXC-201Clinical Data
Updated Phase 1b/2 data as of December 9, 2024
relapsed/refractory AL Amyloidosissource ↗
▲Topline ReadoutNXC-201Clinical Data
Positive data from first four patients announced
relapsed/refractory AL Amyloidosissource ↗
▲Topline ReadoutNXC-201Clinical Data
Positive clinical data announced: 75% complete response rate in 16 patients
relapsed/refractory AL Amyloidosissource ↗
Past FDA Catalysts and PDUFA Decisions
How IMMX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | NXC-201 (NEXICART-2) | Phase 2 topline data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C43 / 100
Pipeline Score
$21M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 32%
Micro Cap(rank 212 of 660)
Percentile Rank
Immix Biopharma, Inc. carries a moderate pipeline score (43/100), with $53M risk-adjusted pipeline value, led by NXC-201 in Dose Escalation and Safety (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NXC-201 CAR-TNCT06097832 | Light Chain (AL) Amyloidosis | Phase 3 | ACTIVE NOT_RECRUITING | 305 | Jan 1, 2039 |
Clinical Trial Results
Readouts, endpoints and source filings for every IMMX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| NXC-201 BreakthroughRMATOrphan | relapsed/refractory AL Amyloidosis | Phase 2 | 2026-09-29 | 89% (40/45) complete response rate; 100% (25/25) of new patients are either in complete response or MRD-negative; 21/25 are in CR; 4/25 are MRD-negative; potentially increasing future CR rate up to 98% (44/45)Read More | Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL AmyloidosisRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Adams Helen C.Director | Grant/Award | 6,250 181,004 held | $0.00 | 05/22/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IMMX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 0.4 % | 28.61 M | 2.77 M |
IMMX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IMMX ranks across every disease it competes in
Competitive Position is a premium feature
See how IMMX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIMMX News
IMMXImmix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
Immix Biopharma, Inc. will present at the 45th Annual J.P. Morgan Healthcare Conference from January 11-14, 2027, in San Francisco. The company is recognized for its work in AL Amyloidosis and is advancing its lead candidate, NXC-201, which has received Breakthrough Therapy Designation and other regulatory recognitions. A replay of the presentation will be available on the company's website.
Read more →IMMXImmix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
Immix Biopharma has successfully closed a $125 million underwritten offering of common stock, with net proceeds of approximately $117.1 million. The funds will be utilized for the development of NXC-201, working capital, and general corporate purposes. The offering was managed by J.P. Morgan and included participation from notable biotechnology investors. NXC-201 is under evaluation for relapsed/refractory AL Amyloidosis and has received significant designations from the FDA.
Read more →IMMX▼ -8.1%on this newsshared move
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
Immix Biopharma has announced the pricing of an underwritten offering of 11,363,637 shares of common stock at $11.00 per share, aiming to raise $125 million. The proceeds will fund the development of their lead candidate, NXC-201, and support working capital. The offering is set to close around September 30, 2026, pending customary conditions.
Read more →IMMX▼ -8.1%on this newsshared move
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
Immix Biopharma reported an interim update showing an 89% complete response rate for its NXC-201 therapy in relapsed/refractory AL Amyloidosis patients. All new patients are either in complete response or MRD-negative, with no relapses observed. The company anticipates a potential increase in the complete response rate to 98% based on MRD-negativity. The final readout and BLA submission for NEXICART-2 are planned for mid-2027.
Read more →IMMX▲ +10.8%on this news
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Immix Biopharma, a leader in AL Amyloidosis treatment, will participate in the Morgan Stanley 24th Annual Global Healthcare Conference from September 14-16, 2026. The company plans to host institutional investor meetings during the event. NXC-201, its lead CAR-T therapy, is under evaluation in a multi-center study and has received significant FDA designations.
Read more →IMMXImmix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
Immix Biopharma has successfully closed a $150 million underwritten offering of common stock, selling 16,778,524 shares at $8.94 each. The net proceeds from this offering are approximately $140.65 million, which will support the company's initiatives in treating AL Amyloidosis. The offering was well-received by prominent U.S. biotechnology institutional investors.
Read more →IMMXImmix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
Immix Biopharma announced a 95% complete response rate in its NEXICART-2 clinical trial for relapsed/refractory AL Amyloidosis. All four MRD-negative patients converted to complete response within one year, with no relapses reported. The company plans to initiate a Phase 3 trial for newly diagnosed patients and expects to present further data in September 2026.
Read more →IMMXImmix Biopharma Announces 95% complete response rate in interim update from relapsed/refractory AL Amyloidosis Clinical Trial
Immix Biopharma has announced an interim update from its NEXICART-2 clinical trial, indicating a 95% complete response rate among the first 20 patients treated for relapsed/refractory AL Amyloidosis. All four MRD-negative patients converted to complete response, and there have been no relapses among patients who reached a complete response within one year of follow-up. The company plans to initiate a randomized Phase 3 trial targeting newly diagnosed AL Amyloidosis patients and anticipates presenting further updates in late September 2026.
Read more →IMMXImmix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
Immix Biopharma has announced a $150 million underwritten offering of 16,778,524 shares of its common stock priced at $8.94 per share. The proceeds are intended to fund the development of NXC-201, working capital, and other corporate purposes, with plans to meet operational needs until mid-2028. The offering is subject to customary closing conditions and is expected to finalize around May 22, 2026. The company is a leader in AL Amyloidosis treatment and NXC-201 has achieved breakthrough designation from the FDA for this indication.
Read more →IMMX▲ +11.4%on this news
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
Immix Biopharma, a leader in treating relapsed/refractory AL Amyloidosis, will participate in the Jefferies Global Healthcare Conference from June 2-4, 2026. The company will host institutional investor meetings and provide access to a replay of the event on their website. Their lead candidate, NXC-201, is under evaluation in a multi-center study and has received significant FDA designations.
Read more →IMMX▲ +5.3%on this news
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
Immix Biopharma has completed enrollment for its BLA-enabling NEXICART-2 trial for relapsed/refractory AL Amyloidosis, with topline results anticipated in Q3 2026. The company has also appointed a new Chief Medical Officer to oversee the BLA submission process. If successful, NXC-201 could become the first FDA-approved treatment for this condition.
Read more →IMMXImmix Biopharma to Participate in Upcoming Investor Conferences
Immix Biopharma, Inc. announced its participation in upcoming investor conferences, including the Leerink Partners 2026 Global Healthcare Conference and the Citizens Life Sciences Conference. Company management will host one-on-one meetings with interested investors. ImmixBio is recognized for its innovative CAR-T cell therapy, NXC-201, which targets relapsed/refractory AL Amyloidosis and has received significant regulatory designations.
Read more →IMMXImmix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
Immix Biopharma has been granted Breakthrough Therapy Designation by the FDA for NXC-201, aimed at treating relapsed/refractory AL Amyloidosis. This designation is based on positive interim results from the NEXICART-2 Phase 2 clinical trial. The company anticipates final data later this year, followed by a planned Biologics License Application submission.
Read more →IMMX▲ +7.3%on this news
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Immix Biopharma, Inc. has announced the successful closing of an upsized underwritten offering of $100 million, which includes approximately 19.1 million shares of common stock and pre-funded warrants. The offering attracted notable interest from leading U.S. biotechnology institutional investors and mutual funds. Following the deduction of offering expenses, Immix expects to receive about $93.7 million in net proceeds, which will bolster its development efforts. The offering was managed by Morgan Stanley, with additional support from Citizens Capital Markets and Mizuho.
Read more →IMMX▲ +10.6%on this news· ran to +33% by day 3shared move
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
Immix Biopharma reported promising Phase 2 results for NXC-201 at ASH 2025, showing a 75% complete response rate in patients with relapsed/refractory AL Amyloidosis. The therapy may further improve outcomes, with predictions of a 95% response rate based on MRD negativity. A BLA submission is anticipated in 2026, reflecting significant advancements in treatment options.
Read more →IMMX▲ +10.6%on this news· ran to +33% by day 3shared move
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Immix Biopharma has announced the pricing of an upsized $100 million underwritten offering of common stock and pre-funded warrants. The offering includes 19,117,646 shares priced at $5.10 each and is expected to close by December 9, 2025. Proceeds will fund the development of NXC-201 and support operational needs through mid-2027.
Read more →IMMX▲ +15.2%on this news
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
Immix Biopharma has appointed Michael Grabow as Chief Commercial Officer to lead the launch of NXC-201, a promising therapy for relapsed/refractory AL Amyloidosis. This disease currently lacks FDA-approved treatments, highlighting the urgency of NXC-201's introduction. The therapy has received both Regenerative Medicine Advanced Therapy and Orphan Drug Designations from the FDA, positioning it as a potential breakthrough in treatment.
Read more →IMMXImmix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
Immix Biopharma announced that interim results from its Phase 1/2 NXC-201 NEXICART-2 trial for relapsed/refractory AL Amyloidosis will be presented at ASH 2025. The trial aims to evaluate the efficacy of NXC-201, a CAR-T cell therapy. The market for AL Amyloidosis treatments is projected to grow significantly, highlighting the potential impact of this therapy.
Read more →About Immix Biopharma, Inc.
Headquarters11400 WEST OLYMPIC BLVD., LOS ANGELES, CA, 90064
BIOPHARMAWATCH ELITE PLUS
Trade the next IMMX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime